Mouse Igm Antibody To Rbd-Spike?

Anti-Spike-RBD-human-mAb(IgM)

E24AHA005 Humanized-Monoclonal-Antibody.human-IgM
EUR 416.5
Description: Humanized Monoclonal Antibody.human IgM

Human IgG antibody Laboratories manufactures the mouse igm antibody to rbd-spike? reagents distributed by Genprice. The Mouse Igm Antibody To Rbd-Spike? reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact igm antibody. Other Mouse products are available in stock. Specificity: Mouse Category: Igm Group: Antibody To

Anti-SARS-CoV-2 Antibody IgG Quantitative and Titer Detection Kit (Spike RBD)

96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective Assay kit detecting the levels of anti-SARS-CoV-2 in human serum can facilitate research on characterization of antibodies produced in response to SARS-CoV-2 infection.

GENLISA™ Mouse SARS-CoV-2 IgG Antibody To Spike RBD Protein ELISA (Quantitative)

12 × 8 wells
EUR 2002.5

SARS-CoV-2 Spike RBD Protein IgG Antibody ELISA Kit

96T
EUR 280

Anti-Spike-RBD-Antibody(R15-F7)

N/A
EUR 157.5
Description: N/A

SARS-CoV-2-Spike-RBD-Antibody

N/A
EUR 346.5
Description: N/A

GENLISA Human Anti-SARS-CoV-2 IgG Antibody to Spike RBD Protein ELISA (Quantitative) - CE MARKED

1 x 96 wells
EUR 379.5

GENLISA Rat Anti-SARS-CoV-2 IgG Antibody to Spike RBD protein Quantitative TITRATION ELISA

1 x 96 wells
EUR 550

Antibody To information

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-2000 2000
EUR 1565.2
Description: Primary VHH single domain antibody

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-250 250
EUR 246.17
Description: Primary VHH single domain antibody

anti-SARS-CoV-2 spike RBD VHH antibody

JOT0007-1-50 50
EUR 89.54
Description: Primary VHH single domain antibody

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (AS113) (Omicron Specific)

SPD-M305 100ug
EUR 5927.8
Description: The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike RBD. The antibody is specific against the Omicron (B.1.1.529/BA.1) variant of SARS-CoV-2, and has no binding with the spike RBD of the wild type virus and other viral lineages.

SARS-CoV-2 Spike RBD protein antibody pair 1

CSB-EAP33245 1 pair
EUR 900
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA.

Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (AS106) (Beta & Gamma Specific)

SPD-M416 100ug
EUR 5703.1
Description: The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike RBD. The antibody is specific against the Beta (B.1.351) and Gamma (P.1) variant of SARS-CoV-2, and has no binding with the spike RBD of the wild type virus, the Alpha (B.1.1.7) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529, BA.2) variant.

Anti-SARS-CoV-2 Spike RBD Broadly Antibody, Mouse IgG1 (2G7F5) (MALS verified)

SPD-Y68 100ug
EUR 2493.1
Description: Anti-SARS-CoV-2 Spike RBD Broadly Antibody, Mouse IgG1 Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike protein.

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

9087-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

9087-biotin-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Mouse monoclonal Anti-MERS Spike protein RBD (MES-RBD) IgG1 (neutralizing)

MERS125-M 100 ul
EUR 578.4

Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (9A6A11) (XBB.1.5/Omicron Specific)

SPD-Y168 1mg
EUR 374.5
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (5C5C10) (BQ.1.1/Omicron Specific)

SPD-Y170 1mg
EUR 374.5
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (5F8E1) (XBB.1.5/Omicron Specific)

SPD-Y171 1mg
EUR 374.5
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5]

SD9431-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5]

SD9431-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).